#layerFE1F53E28A8D30C87369ACA4EF2C2E33 .search_btn {border: 0px solid #fff;border-radius: 0px;color: #fff;}#layerFE1F53E28A8D30C87369ACA4EF2C2E33 .search_btn a {color: #fff!important;}#layerFE1F53E28A8D30C87369ACA4EF2C2E33 .search_btn:hover {background-color: #000!important;border-color: #fff;color: #fff;}#layerFE1F53E28A8D30C87369ACA4EF2C2E33 .search_btn:hover a {color: #fff!important;}

Zillion Bio is an R&D-stage biotechnology company committed to translating innovative biological discoveries in cell and gene therapy into viable treatments for cancer and rare diseases. Zillion Bio possesses robust in-house R&D capabilities. It has developed the patented ZiCAR platform, an advanced CAR-T therapy solution for a spectrum of cancers, with a leading program on hepatocellular carcinoma (HCC).

Our Mission is to pioneer and provide groundbreaking technologies, craft therapeutic products that address critical patient needs, and uphold scalable and dependable manufacturing processes to deliver consistent quality and care.

 

   

The differentiated technology and platforms

    

      The differentiated intracellular Z-domain is engineered to produce a subtype of CAR-T cells known as Tscm (T memory stem cells), which exhibit superior stemness properties. These cells are further armored with cytokines to bolster their anti-tumor activity. This advanced approach positions our technology at the forefront of providing safe and effective CAR-T therapy for solid tumors, adeptly tackling the challenges of T cell exhaustion and the immunosuppressive tumor microenvironment.

Lear More

Platform technologies serve as building blocks for innovation

  

In-house R&D platforms with strong global intellectual property position

  • 01

    ZiCAR a CAR-T platform to break through solid tumor treatment

    • · First in human clinical trial ongoing
    • · Better safety profile, faster manufacture and lower cost
    • · Competitive technology to extend T cell persistence
    • · Versatile platform for diverse and multiple targets
    • · Autologous, allogeneic, and in-vivo compatible
  • 02

    ZiAST an adenovirus-based targeting platform to cope with tumor antigen escape

    • · First reported engineered oncolytic virus (OV) platform to cope with antigen escape in conjunction with CAR-T
    • · Proof of mechanism achieved
    •  
  • 03

    ZeuCAR an allogenic CAR-T platform to reduce cost & improve accessibility

    • · Off-the-shelf Car-T platform
    • · Future adaptation into other therapeutic areas include aging and autoimmune diseases
    •  

ZiCar

Products with a High % of Tscm Cells

  •  

ZiCAR-002 IN VIVO EFFICACY IN XENOGRAFT NCG MODEL

CONTACT US

    info@zillion.org.cn